Proclara’s therapies are designed to simultaneously target multiple misfolded proteins implicated in neurodegenerative and other diseases.
Our lead product candidate, NPT088, is currently in clinical development for the treatment of Alzheimer’s disease. We are also advancing preclinical programs in a broad range of neurodegenerative and systemic amyloidosis diseases.
Upcoming trials will be listed on clinicaltrials.gov as they are launched.
Proclara Bioscience’s lead development program, NPT088, is a fusion protein combining GAIM with the backbone of a human immunoglobulin, and is delivered by intravenous administration. Because it acts on both protein aggregates implicated in Alzheimer’s disease – amyloid-β (Aβ) and tau – NPT088 may be better suited to treat the complex pathophysiology of the disease than other monotherapies currently in development.
Proclara recently completed a Phase 1a safety study of NPT088 involving 40 healthy volunteers, which demonstrated that a single administration appears to be both safe and well tolerated at multiple dose levels.
We are currently conducting a Phase 1b study of NPT088, which will enroll up to 66 patients diagnosed with probable Alzheimer’s disease. The randomized, double-blind, placebo-controlled study will evaluate the safety and tolerability of multiple doses of NPT088, as well as pharmacokinetics, immunogenicity and pharmacodynamic (effects on biomarkers) characteristics.
Next Generation Candidates
In addition to our lead drug candidate, Proclara is also developing next generation candidates using our GAIM technology platform with attributes that may deliver potential benefits to patients suffering from a broad range of neurodegenerative and systemic amyloidosis diseases. NPT289, which is currently in preclinical development, may be effective in Alzheimer’s and Parkinson’s disease, or in orphan indications including rare systemic amyloidosis diseases. Additionally, we believe our approach may also have a significant impact on neuro-orphan indications including Progressive Supranuclear Palsy, Huntington’s disease, and Creutzfeldt-Jacob disease.